ArticleJAMA2023
Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.
Article in JAMA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Repurposing trazodone for Alzheimer's disease to modulate soluble ST2 levels and alleviate Alzheimer's pathology.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- MRI In Vivo Detection of Amyloid-β Protein Deposition in Different Brain Regions of Patients with AD and MCI.Brain topography · 2026Article
- Defining patient-centered amyloid PET thresholds for the onset of tauopathy in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Neuropathologically validated MRI to tau PET synthesis via Covariate-modulated attention networks.bioRxiv : the preprint server for biology · 2025Article
- Enhancing diagnostic precision in Alzheimer's disease: Impact of comorbidities on blood biomarkers for clinical integration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Proteogenomic signature of Alzheimer's disease and related dementia risk in individuals with major depressive disorder.Nature. Mental health · 2025Article
- Brain metabolic imaging-based model identifies cognitive stability in prodromal Alzheimer's disease.Scientific reports · 2025Article
- Favorable long-term cognitive outcomes following recurrent ARIA linked to amyloid-lowering therapies: two cases.Journal of neurology · 2025Article
- Standardized statistical framework for comparison of biomarkers: Techniques from ADNI.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Predicting how many people might receive treatment with new therapies for Alzheimer's disease.Journal of neurology, neurosurgery, and psychiatry · 2024Article
- Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer's disease.PLoS biology · 2024Article
- A Framework for Best Practices and Readiness in the Advent of Anti-Amyloid Therapy for Early Alzheimer's Disease in Asia.Journal of Alzheimer's disease : JAD · 2024Review
- Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease.Nature communications · 2023Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
38112817What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.